TP53 and cancer: It has been reported that increased sensitivity to WEE1 inhibition through mechanisms outside of cell‐cycle checkpoint defects, such as DDR aberrations and nucleotide resource starvation, with single‐agent activity observed even in TP53‐wild‐type cancer cells.387, 388, 389, 390